>Tratamento de terapia com células CAR-T da Ásia-Pacífico, por produto (células CAR-T autólogas, células CAR-T alogénicas), estrutura (células CAR-T de primeira geração, células Car-T de segunda geração, células CAR- T de terceira geração, quarta Geração de células CAR-T), antigénios dirigidos (antigénios em tumores sólidos, antigénios em doenças malignas hematológicas, outros), marca (Yescarta, Kymriah, Tecartus, outros), aplicação terapêutica (malignidades hematológicas, cancro do pâncreas, cancro da mama, cancro do pulmão, gástrico Cancro , Mieloma Múltiplo, Leucemia Linfocítica Crónica, Linfoma de Células do Manto, Linfoma Folicular, Linfoma Difuso de Grandes Células B, Leucemia Linfoblástica Aguda, Outros), Utilizador Final (Hospitais, Clínicas Especializadas , Outros), Canal de Distribuição (Hospitais Farmácia, Outros), País (Japão, China, Austrália, Índia, Coreia do Sul, Singapura, Indonésia, Tailândia, Malásia, Filipinas, Vietname, Resto da Ásia-Pacífico) Tendências e previsões da indústria para 2028
Análise de mercado e insights : Mercado de tratamento de terapia celular CAR-T da Ásia-Pacífico
Espera-se que o mercado de tratamento de terapia celular CAR-T da Ásia-Pacífico ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 30,8% no período de previsão de 2021 a 2028 e deverá atingir os 267,08 milhões de dólares até 2028. O aumento da utilização da terapia celular CAR-T para o tratamento do cancro e de doenças infeciosas e o aumento da prevalência do cancro são os principais impulsionadores que impulsionaram a procura do mercado no período de previsão.
O tratamento de terapia celular CAR-T compreende características que a crescente necessidade de produtos seguros e eficazes terá impacto no lançamento de novos produtos pelos fabricantes no mercado que aumentam a sua procura, bem como o aumento do investimento em investigação e desenvolvimento leva ao crescimento do mercado. Espera-se que o aumento do investimento na investigação sobre o desenvolvimento da terapia celular CAR-T proporcione várias outras oportunidades no mercado de tratamento da terapia celular CAR-T. No entanto, os efeitos secundários adversos das terapêuticas e o elevado custo associado às terapêuticas deverão restringir o crescimento do mercado no período de previsão.
A procura pelo tratamento com terapia com células CAR-T tem aumentado tanto nos países desenvolvidos como nos países em desenvolvimento e a razão por detrás disto é o aumento da sensibilização para as imunoterapias para o tratamento com terapia com células CAR-T e o aumento do investimento em investigação e desenvolvimento. O mercado de tratamento de terapia celular CAR-T crescerá no período previsto com o aumento da prevalência de cancros.
Espera-se que os efeitos secundários adversos das terapias e o elevado custo associado às terapias restrinjam o crescimento do mercado de tratamento de terapia celular CAR-T.
The CAR-T cell therapy treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.
Asia-Pacific CAR-T Cell Therapy Treatment Market Scope and Market Size
CAR-T cell therapy treatment market is segmented on the based on the basis of product, structure, targeted antigens, brand, therapeutic application, end user, distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product, the CAR-T cell therapy treatment market is segmented into autologous CAR-T cells and allogeneic CAR-T cells. In 2021, autologous CAR-T cells segment is expected to dominate the CAR-T cell therapy treatment market because the drugs approved for CAR-T cell therapy are autologous in nature. These cells are easy to manufacture because they are derived from the patient own cells or plasma. Moreover, intensive research is ongoing on autologous cells.
- On the basis of structure, the CAR-T cell therapy treatment market is segmented into first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells and fourth generation CAR-T cells. In 2021, second generation CAR-T cells segment is expected to dominate the CAR-T cell therapy treatment market because the approved therapies are second generation based structure. Moreover, second generation are highly specific in nature which recognizes and binds tumor specific antigens.
- On the basis of targeted antigens, the CAR-T cell therapy treatment market is segmented into antigens on solid tumors, antigens on hematologic malignancies and others. In 2021, antigens on hematologic malignancies segment is expected to dominate the CAR-T cell therapy treatment market because drugs approved for CAR-T cell therapy are majorly used for hematologic malignancies and ongoing extensive research development.
- On the basis of brand, the CAR-T cell therapy treatment market is segmented into yescarta, kymriah, tecartus and others. In 2021, yescarta segment is expected to dominate the CAR-T cell therapy treatment market because yescarta is the first approved CAR-T cell therapy for oncology therapeutic class. Moreover, yescarta accounts the highest sale.
- On the basis of therapeutic application, the CAR-T cell therapy treatment market is segmented into hematological malignancies, pancreatic cancer, breast cancer, lung cancer, gastric cancer, multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, acute lymphoblastic leukemia and others. In 2021, hematological malignancies segment is expected to dominate the CAR-T cell therapy treatment market because yescarta accounts the major revenue in the market and the follicular lymphoma is the major indication for yescarta.
- On the basis of end user, the CAR-T cell therapy treatment market is segmented into hospitals, specialty clinics and others. In 2021, hospitals segment is dominating the CAR-T cell therapy treatment market because CAR-T cell therapy required highly trained professionals with advanced technology laboratories. So, the hospitals have all the advanced equipment and technology with trained professionals.
- On the basis of distribution channel, the CAR-T cell therapy treatment market is segmented into hospitals pharmacy and others. In 2021, hospitals pharmacy segment is expected to dominate the CAR-T cell therapy treatment distribution channel because hospitals pharmacy are the central part of the hospitals, all the infusion related and medication related delivery sold by the pharmacy department.
CAR-T Cell Therapy Treatment Market Country Level Analysis
The CAR-T cell therapy treatment market is analyzed and market size information is provided on the basis of product, structure, targeted antigens, brand, therapeutic application, end user, distribution channel as referenced above.
The countries covered in the CAR-T cell therapy treatment market report are the Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, and Rest of Asia-Pacific.
Autologous CAR-T cells segment in Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 due to continuous research and development related to the CAR-T cell therapy. Japan is leading the growth of the Asia-Pacific market and autologous CAR-T cells segment is dominating in this country because due to increasing healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rise in Awareness about Immunotherapies and Increasing Investment in Research and Development are Boosting the Market Growth of CAR-T Cell Therapy Treatment Market
CAR-T cell therapy treatment market also provides you with detailed market analysis for every country growth in CAR-T cell therapy treatment industry with CAR-T cell therapy treatment drugs sales, impact of advancement in the CAR-T cell therapy treatment technology and changes in regulatory scenarios with their support for the CAR-T cell therapy treatment market. The data is available for historic period 2010 to 2019.
Competitive Landscape and CAR-T Cell Therapy Treatment Market Share Analysis
CAR-T cell therapy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to CAR-T cell therapy treatment market.
The major companies which are dealing in the CAR-T cell therapy treatment are Autolus, Amgen Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., AbbVie Inc., Novartis AG, Cartherics Pty ltd, CARINA BIOTECH, and TC BIOPHAR Mamong others global and domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the CAR-T cell therapy treatment market.
For instance,
- In February 2021, AbbVie Inc. had announced the collaboration with the Caribou Biosciences which is the biotechnology leading company in the clinical-stage CRISPR genome editing. The companies have entered into the collaboration and license agreement for the research and development of the chimeric antigen receptor (CAR)-T cell therapeutics. The allogeneic CAR-T cell therapies showed positive impact on the cancer patients but the rejection of CAR-T cells by the host immune system has been considered as one of the challenge for the researchers therefore, Caribou Biosciences technology that is CRISPR genome editing will be engineered to the CAR-T cells so that it can endure the host immune attack which can benefit the large patient population. This collaboration helped the company to be considered in the market who is involved in the development of the innovative CAR-T therapies and overcome the issues related with this therapy which will increase the status in the market and directly increases their company growth.
- Em julho de 2020, a Kite Pharma (uma subsidiária da Gilead Sciences, Inc.) anunciou que a empresa recebeu a aprovação da USFDA para o Tecartus (brexucabtagene autoleucel), que era anteriormente conhecido como KTE-X19, considerado apenas como terapia com células CAR -T. O produto foi atribuído com Breakthrough Therapy Designation (BTD) da FDA. A infusão única deste produto revelou que 62% apresentaram uma resposta completa e 87% dos doentes responderam positivo. Este produto é considerado a primeira terapêutica celular para doentes que sofrem de LCM recidivante/refratário. Isto ajudou a empresa a ser reconhecida como uma das empresas a desenvolver uma terapia com células CAR-T para o tratamento do linfoma refratário de grandes células B após as duas ou três terapias que aumentarão a procura no mercado.
A colaboração, o lançamento de produtos, a expansão do negócio, a premiação e o reconhecimento, as joint ventures e outras estratégias do player de mercado estão a melhorar o mercado da empresa no mercado de tratamento de terapia celular CAR-T, que também oferece o benefício para a organização melhorar a sua oferta de CAR-T terapia celular.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET PRODUCT COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN USAGE OF CAR-T CELL THERAPY FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES
7.1.2 INCREASING PREVALENCE OF CANCER
7.1.3 RISE IN AWARENESS ABOUT IMMUNOTHERAPIES
7.1.4 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT
7.1.5 ADOPTION OF CAR-T CELL THERAPY TREATMENT IN EMERGING MARKETS
7.2 RESTRAINTS
7.2.1 ADVERSE SIDE EFFECTS OF THERAPIES
7.2.2 HIGH COST ASSOCIATED WITH THERAPIES
7.2.3 LOGISTIC CHALLENGE ASSOCIATED WITH CAR-T THERAPIES
7.2.4 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT
7.3 OPPORTUNITIES
7.3.1 PRESENCE OF PIPELINE PRODUCTS
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR
7.4 CHALLENGES
7.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES
7.4.2 LACK OF SKILLED PROFESSIONALS
8 IMPACT OF COVID-19 ON ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISION FOR MANUFACTURERS
8.5 CONCLUSION
9 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 AUTOLOGOUS CAR-T CELLS
9.3 ALLOGENEIC CAR-T CELLS
10 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE
10.1 OVERVIEW
10.2 FIRST GENERATION CAR-T CELLS
10.3 SECOND GENERATION CAR-T CELLS
10.4 THIRD GENERATION CAR-T CELLS
10.5 FOURTH GENERATION CAR-T CELLS
11 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET, BY TARGETED ANTIGENS
11.1 OVERVIEW
11.2 ANTIGENS ON HEMATOLOGIC MALIGNANCIES
11.2.1 CLUSTER OF DIFFERENTIATION-19 (CD-19)
11.2.2 CLUSTER OF DIFFERENTIATION-30 (CD-30)
11.2.3 CLUSTER OF DIFFERENTIATION-22 (CD-22)
11.2.4 CLUSTER OF DIFFERENTIATION-20 (CD-20)
11.2.5 CLUSTER OF DIFFERENTIATION-33 (CD-33)
11.3 ANTIGENS ON SOLID TUMORS
11.3.1 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER-2)
11.3.2 EPIDERMAL GROWTH FACTOR RECEPTORS VARIANT III (EGFRV-III)
11.3.3 MESOTHELIN (MSLN)
11.3.4 PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)
11.3.5 INTERLEUKIN-13RA2 (IL13RA2)
11.3.6 DISIALOGANGLIOSIDE 2 (GD2)
11.3.7 GLYPICAN-3 (GPC3)
11.3.8 OTHERS
11.4 OTHERS
12 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND
12.1 OVERVIEW
12.2 YESCARTA
12.3 KYMRIAH
12.4 TECARTUS
12.5 OTHERS
13 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION
13.1 OVERVIEW
13.2 FOLLICULAR LYMPHOMA
13.3 DIFFUSE LARGE B-CELL LYMPHOMA
13.4 ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)
13.5 MANTLE CELL LYMPHOMA
13.6 MULTIPLE MYELOMA
13.7 HEMATOLOGIC MALIGNANCIES
13.7.1 LEUKEMIA
13.7.2 LYMPHOMA
13.7.3 MYELOMA
13.7.4 OTHERS
13.8 LUNG CANCER
13.9 CHRONIC LYMPHOCYTIC LEUKEMIA
13.1 GASTRIC CANCER
13.11 PANCREATIC CANCER
13.12 BREAST CANCER
13.13 OTHERS
14 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 OTHERS
15 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 OTHERS
16 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET BY GEOGRAPHY
16.1 ASIA-PACIFIC
16.1.1 JAPAN
16.1.2 AUSTRALIA
16.1.3 SINGAPORE
16.1.4 CHINA
16.1.5 SOUTH KOREA
16.1.6 INDIA
16.1.7 MALAYSIA
16.1.8 THAILAND
16.1.9 INDONESIA
16.1.10 PHILIPPINES
16.1.11 VIETNAM
16.1.12 REST OF ASIA-PACIFIC
17 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 KITE PHARMA (A SUBSIDIARY OF GILEAD SCIENCES, INC.)
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 NOVARTIS AG
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 ABBVIE INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 PRODUCT PORTFOLIO
19.3.4 RECENT DEVELOPMENTS
19.4 ADAPTIMMUNE THERAPEUTICS PLC
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENTS
19.5 AMGEN INC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PIPELINE PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENTS
19.6 ATARA BIOTHERAPEUTICS, INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 PIPELINE PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENTS
19.7 AURORA BIOPHARMA
19.7.1 COMPANY SNAPSHOT
19.7.2 PIPELINE PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 AUTOLUS
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 BELLICUM PHAMACEUTICALS, INC.
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENTS
19.1 BIOATLA INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENTS
19.11 BLUEBIRD BIO, INC.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 BRISTOL-MYERS SQUIBB COMPANY
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 CARINA BIOTECH
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 CARTHERICS PTY LTD
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 CARTESIAN THERAPEUTICS, INC.
19.15.1 COMPANY SNAPSHOT
19.15.2 PIPELINE PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 CELLECTIS SA
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 CELYAD ONCOLOGY SA
19.17.1 COMPANY SNAPSHOT
19.17.2 PIPELINE PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 JOHNSON & JOHNSON SERVICES, INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 SORRENTO THERAPEUTICS, INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 PIPELINE PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS
19.2 TC BIOPHARM LIMITED
19.20.1 COMPANY SNAPSHOT
19.20.2 PIPELINE PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
19.21 TESSA THERAPEUTICS LTD.
19.21.1 COMPANY SNAPSHOT
19.21.2 PIPELINE PRODUCT PORTFOLIO
19.21.3 RECENT DEVELOPMENTS
19.22 TMUNITY THERAPEUTICS
19.22.1 COMPANY SNAPSHOT
19.22.2 PIPELINE PRODUCT PORTFOLIO
19.22.3 RECENT DEVELOPMENTS
19.23 MUSTANG BIO
19.23.1 COMPANY SNAPSHOT
19.23.2 PIPELINE PRODUCT PORTFOLIO
19.23.3 RECENT DEVELOPMENTS
19.24 XYPHOS (A SUBSIDIARY OF ASTELLAS PHARMA INC.)
19.24.1 COMPANY SNAPSHOT
19.24.2 REVENUE ANALYSIS
19.24.3 PIPELINE PRODUCT PORTFOLIO
19.24.4 RECENT DEVELOPMENTS
19.25 ZIOPHARM ONCOLOGY, INC.
19.25.1 COMPANY SNAPSHOT
19.25.2 PRODUCT PORTFOLIO
19.25.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tabela
TABLE 1 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 BELOW PROVIDED ARE THE ALTERNATIVE CHEMOTHERAPIES OF CAR-T CELL THERAPY:
TABLE 3 TOTAL HEALTH SPENDING BY THE U.S. (2015-2016)
TABLE 4 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET, BY MOLECULE, 2019-2028 (USD MILLION)
TABLE 5 ASIA-PACIFIC AUTOLOGOUS CAR-T CELLS IN CAR-T CELL THERAPY TREATMENTMARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC ALLOGENEIC CAR-T CELLS IN CAR-T CELL THERAPY TREATMENTMARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET, BY STRUCTURE, 2019-2028 (USD MILLION)
CELYAD IS ENGAGED IN THE MANUFACTURING OF CYAD-211, A FIRST GENERATION CAR-T CELL THERAPY EXPRESSING BCMA TARGETING CHIMERIC ANTIGEN RECEPTOR WHICH INTERFERES WITH THE EXPRESSION OF THE CD3Ζ OF T CELL RECEPTOR COMPLEX.
TABLE 8 ASIA-PACIFIC FIRST GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC SECOND GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC THIRD GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC THIRD GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY ANTIGENS ON HEMATOLOGIC MALIGNANCIES, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENTMARKET , BY REGION, 2017-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY ANTIGENS ON SOLID TUMORS, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC OTHERS IN CAR-T CELL THERAPY TREATMENTMARKET , BY REGION, 2017-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC YESCARTA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC YESCARTA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC KYMRIAH IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC TECARTUS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC FOLLICULAR LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2017-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC DIFFUSE LARGE B-CELL LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC MANTLE CELL LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC MULTIPLE MYELOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC LUNG CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC GASTRIC CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC PANCREATIC CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 35 ASIA-PACIFIC BREAST CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 36 ASIA-PACIFIC OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 37 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 ASIA-PACIFIC HOSPITALS IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2017-2028 (USD MILLION)
TABLE 39 ASIA-PACIFIC SPECIALTY CLINICS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 40 ASIA-PACIFIC OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 41 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 42 ASIA-PACIFIC HOSPITAL PHARMACY IN CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2028 (USD MILLION)
TABLE 43 ASIA-PACIFIC OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 44 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 46 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 47 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 48 ASIA-PACIFIC ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 49 ASIA-PACIFIC ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 50 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 51 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 52 ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 53 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 54 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 55 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 56 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 57 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 58 JAPAN ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 59 JAPAN ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 60 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 61 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 62 JAPAN HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 63 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 64 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 65 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 66 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 67 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 68 AUSTRALIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 69 AUSTRALIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 70 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 71 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 72 AUSTRALIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 73 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 74 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 75 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 76 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 77 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 78 SINGAPORE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 79 SINGAPORE ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 80 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 81 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 82 SINGAPORE HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 83 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 84 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 85 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 86 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 87 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 88 CHINA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 89 CHINA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 90 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 91 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 92 CHINA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 93 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 94 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 96 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 97 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 98 SOUTH KOREA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 99 SOUTH KOREA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 100 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 101 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 102 SOUTH KOREA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 103 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 104 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 105 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 106 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 107 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 108 INDIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 109 INDIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 110 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 111 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 112 INDIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 113 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 114 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 115 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 116 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 117 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 118 MALAYSIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 119 MALAYSIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 120 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 121 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 122 MALAYSIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 123 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 124 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 125 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 126 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 127 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 128 THAILAND ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 129 THAILAND ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 130 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 131 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 132 THAILAND HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 133 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 134 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 135 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 136 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 137 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 138 INDONESIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 139 INDONESIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 140 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 141 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 142 INDONESIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 143 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 144 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 145 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 146 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 147 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 148 PHILIPPINES ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 149 PHILIPPINES ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 150 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 151 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 152 PHILIPPINES HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 153 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 154 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 155 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 156 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 157 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 158 VIETNAM ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 159 VIETNAM ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 160 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 161 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 162 VIETNAM HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 163 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 164 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 165 REST OF ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
Lista de Figura
FIGURE 1 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: MARKET PRODUCT COVERAGE GRID
FIGURE 11 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION
FIGURE 12 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT IS EXPECTED TO DRIVE THE ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 AUTOLOGUS CAR-T CELLS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET IN 2021 & 2028
FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR THE CAR-T CELL THERAPY TREATMENT MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET
FIGURE 16 NEW CANCER CASES WORLDWIDE, (2018)
FIGURE 17 ASIA-PACIFIC CANCER INCIDENCE (2018)
FIGURE 18 CANCER DEATH BY TYPE (IN MILLION), WORLD, 2017
FIGURE 19 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2021
FIGURE 20 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2019-2028 (USD MILLION)
FIGURE 21 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 22 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2021
FIGURE 24 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2019-2028 (USD MILLION)
FIGURE 25 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, CAGR (2021-2028)
FIGURE 26 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, 2021
FIGURE 28 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
FIGURE 29 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, CAGR (2021-2028)
FIGURE 30 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2020
FIGURE 32 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2020-2028 (USD MILLION)
FIGURE 33 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, CAGR (2020-2028)
FIGURE 34 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, 2020
FIGURE 36 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, 2020-2028 (USD MILLION)
FIGURE 37 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, CAGR (2020-2028)
FIGURE 38 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, 2020
FIGURE 40 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 41 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, CAGR (2020-2028)
FIGURE 42 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 44 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 45 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 46 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 48 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 49 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 51 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY PRODUCT (2021-2028)
FIGURE 52 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
